Affitech A/S announced today that its Russian collaboration partner, IBC Generium, has submitted a Clinical Trial Application (CTA) to the Russian Health Authority to commence a phase 1 clinical trial with Affitech’s leading anti­body drug candidate  AT001/r84.  The product candidate is a new patented human mono­clonal antibody to human vascular endothelial growth factor (VEGF), and is being developed as a potential treatment of cancer. The anti-VEGF antibody will be evaluated in patients with various cancers and is a possible competitor to bevacizumab (Avastin® – Roche).  The Phase 1 clinical trial will start as soon as the Russian CTA has been approved.